Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 78.06M P/E - EPS this Y 62.80% Ern Qtrly Grth -
Income -131.56M Forward P/E -0.79 EPS next Y -29.60% 50D Avg Chg 11.00%
Sales 4.15M PEG - EPS past 5Y - 200D Avg Chg 4.00%
Dividend N/A Price/Book 0.72 EPS next 5Y - 52W High Chg -66.00%
Recommedations 2.00 Quick Ratio 3.22 Shares Outstanding 26.81M 52W Low Chg 57.00%
Insider Own 1.32% ROA -51.11% Shares Float 13.94M Beta 1.58
Inst Own 81.10% ROE -393.39% Shares Shorted/Prior 1.10M/1.24M Price 3.79
Gross Margin - Profit Margin - Avg. Volume 74,632 Target Price 11.00
Oper. Margin -2,835.00% Earnings Date Nov 12 Volume 39,194 Change -3.81%
About Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Syros Pharmaceuticals, Inc. News
11/14/24 Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
11/14/24 Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
11/13/24 Syros stock craters after lead cancer therapy flops in Phase III trial
11/12/24 Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression
11/02/24 Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023)
11/01/24 Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ...
10/31/24 Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
10/24/24 Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
10/09/24 Syros Pharmaceuticals Inc (SYRS) Q2 2024 Earnings Call Highlights: Strategic Focus on ...
09/14/24 Insider Spends US$161k Buying More Shares In Syros Pharmaceuticals
09/12/24 Insider Buying: CFO Jason Haas Acquires 100,000 Shares of Syros Pharmaceuticals Inc (SYRS)
09/12/24 Insider Buying: President & CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc (SYRS)
08/27/24 Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
08/14/24 Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination
08/14/24 Syros Pharmaceuticals (SYRS) Loses -70.55% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
08/13/24 Top Midday Decliners
08/13/24 Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
08/13/24 Syros’ stock craters after Phase II AML trial termination due to inefficacy
08/12/24 Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial
08/05/24 Does Syros Pharmaceuticals (SYRS) Have the Potential to Rally 251.92% as Wall Street Analysts Expect?
SYRS Chatroom

User Image Stud3nt Posted - 16 hours ago

$SYRS we need to break 0.25, the. 0.26 and 0.27 would be much easier to break. Volume is not enough; yet! 🀞🏻☘️✳️

User Image Thomas346 Posted - 17 hours ago

$SYRS 80 cents would make me so happy

User Image Stud3nt Posted - 18 hours ago

$SYRS Maybe today is the day we've been waiting for 🀞🏻☘️✳️

User Image Denaciousrajan Posted - 18 hours ago

$SYRS come on man

User Image JohRot777 Posted - 21 hours ago

@NVDAMillionaire Hi there. I get a feeling that you have good knowledge about $SYRS so my question to you is, are the article you shared positive for the future? I'm from Sweden so my English isn't so good to understand everything. Hope you can answer when you have some time over.

User Image NVDAMillionaire Posted - 1 day ago

$SYRS Syros Pharmaceuticals (SYRS): A Biopharmaceutical Firm Committed to Advancing Hematologic Malignancy Treatments https://beyondspx.com/article/syros-pharmaceuticals-syrs-a-biopharmaceutical-firm-committed-to-advancing-hematologic-malignancy-treatments

User Image Luckiest_Man_Alive Posted - 1 day ago

$SYRS Looks like I am the only one still buying here πŸ™ƒπŸ˜‡βœŒοΈβš‘οΈπŸŒΉπŸ•ŠοΈπŸŒπŸŒžπŸŽπŸ€πŸ‘‘πŸ”‘

User Image Luckiest_Man_Alive Posted - 1 day ago

$SYRS Still holding here. Usually what ever I touch turns to gold eventually. Let’s see what happens here ! Just breathe! 🧘 πŸ‘ŒπŸ€β€οΈπŸŽ

User Image ICEMAN_kkb Posted - 1 day ago

$SYRS hello?

User Image roejohn Posted - 1 day ago

$SYRS I was more interested in the studies for pancreatic cancer !

User Image Stud3nt Posted - 2 days ago

$SYRS Maybe those institutions that have million dollars investments in Syros have some plans to save their investment (as they change the board and tried to control the situation by going from research mindset to more business mindset). I still think they will recover; but, wish me luck with this one ☘️🀞🏻

User Image Stud3nt Posted - 3 days ago

@Luckiest_Man_Alive Did you got out of $SYRS ? What do you think about it πŸ€”

User Image roejohn Posted - 3 days ago

$SYRS If another pharmaceutical company wants to go public and syrs has cash per share then it would be the perfect shell to bring another company public ! It is the least expensive method . Companies like ASU brought Vons public years ago , many examples ! All the shareholders made mucho dollars buying and holding because vons got out for a huge return by safeway . We need some players like DLJ and Warburg PINUS .. to do a deal like that !

User Image DharlMorey2 Posted - 3 days ago

$ATOS If data is good at SABCS all is fine. Doc either has something lined up or the data is *that good* that they were confident enough to do the 100 million ATM. I don't like the timing personally of the 100 milion cash raise, but I don't see why we don't reach a new 52-week high in ~10 days. This is the biggest data release in Atossa history as far as I'm concerned. If patent is resolved, that'll be a huge catalyst, that seems what the market is hung on. $XBI $AMAM $SYRS

User Image Denaciousrajan Posted - 3 days ago

$SYRS bounce over 27 and I’m out.

User Image bigboy420 Posted - 4 days ago

$SYRS going to RS and delist

User Image Thomas346 Posted - 4 days ago

$SYRS πŸš€πŸš€

User Image BioGem Posted - 6 days ago

$SYRS Building a short position here, especially if it goes above $0.3. Should be filing for Bankruptcy soon: -Cash as of Sep 30th = 60M. Through Q4, I estimate conservatively 15M in cash burn for regular operations and severances, below the 20M/Q as usual. -They also paid back 33M of their 43M loan debt. -Basic math: 60M-15M-33M= 12M remain in December. -They still carry 10M in debt due, and at least an estimate of 20M in current liabilities to CROs, manufacturers, landlord, etc. This means 12M in cash against 30M in liabilities imminently due. -The short interest has skyrocketed from 6% to 33% consistent with my dire expectations.

User Image Luckiest_Man_Alive Posted - 11/29/24

$SYM I getting a position in $SYRS . Still under a 1$ for now. It’s very dangerous, I don’t recommend you to join me in this. πŸ€πŸ€πŸ€πŸ€πŸ€πŸ€πŸ€

User Image sonicstriker Posted - 11/29/24

$SYRS

User Image Denaciousrajan Posted - 11/29/24

$SYRS this shit better go up otherwise I’m learning how to make napalm at home

User Image Thomas346 Posted - 11/28/24

$SYRS no pre market price ?

User Image sonicstriker Posted - 11/27/24

$SYRS

User Image lucabrix Posted - 11/27/24

$SYRS Those macscos of insiders sold at 0.19!!!! LOL

User Image Luckiest_Man_Alive Posted - 11/27/24

$SYRS $XRP.X $BTC.X $TSLA It is indeed possible to earn money in the stock market by exercising patience and having a long-term perspective. Many investors today are focused on quick profits, rushing to sell their holdings at the slightest hint of a new, seemingly more promising opportunity. This short-term mindset leads to missed opportunities for sustained growth. Successful investing requires discipline and the ability to resist the lure of constantly shifting from one stock to another. Investors who remain patient and hold onto well-chosen investments, even during periods of market volatility, are likely to see consistent returns over time. History shows that those who adopt a long-term approach and invest funds they do not need immediately tend to outperform those chasing short-term gains. The key to building wealth in the stock market is not in timing the market but in allowing time in the market to work in your favor. Patience remains the hallmark of successful investing.

User Image Denaciousrajan Posted - 11/27/24

$SYRS go up bitch

User Image sonicstriker Posted - 11/27/24

$SYRS GOGOGOGO!!!!

User Image Luckiest_Man_Alive Posted - 11/27/24

$SYRS Increasing position very very slow. Do not follow me, It’s very dangerous πŸ€

User Image Luckiest_Man_Alive Posted - 11/27/24

$SYRS What a beautiful chart that is… πŸ‘Œβ€οΈ

User Image Luckiest_Man_Alive Posted - 11/27/24

$SYRS Sell everything you got. All of it. . . . . . . . . . To me. πŸ€ (Don’t follow, I am here to lose money)

Analyst Ratings
Piper Sandler Overweight Aug 13, 24
JMP Securities Market Outperform Aug 13, 24
HC Wainwright & Co. Buy Aug 13, 24
HC Wainwright & Co. Buy Aug 1, 24
HC Wainwright & Co. Buy Jun 26, 24
HC Wainwright & Co. Buy May 15, 24
Piper Sandler Overweight Apr 3, 24
HC Wainwright & Co. Buy Apr 1, 24
Piper Sandler Overweight Oct 3, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
AKKARAJU SRINIVAS Director Director Dec 21 Buy 4.42 904,977 3,999,998 1,786,427 12/26/23
Olson Eric R Chief Scientific Off.. Chief Scientific Officer Jul 17 Sell 3.50 689 2,412 6,661 07/18/23
Young Richard A Director Director Feb 10 Sell 8.87 5,990 53,131 329,211 02/10/21
Simonian Nancy A President & CEO President & CEO Dec 21 Option 7.21 29,917 215,702 563,606 12/21/20
Young Richard A Director Director Nov 18 Sell 8.87 5,990 53,131 339,211 11/18/20